Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464308 | 0.89 | MEN1 (0.53) | MEN1KMT2AGAAMAPK8P2RX7 | |
| SCHEMBL5477278 | 0.85 | KMT2A (0.58) | MEN1KMT2AMAPK8HTTP2RX7 | |
| SCHEMBL5465081 | 0.84 | KMT2A (0.61) | MEN1KMT2AGAAMAPK8HTT | |
| SCHEMBL5471267 | 0.83 | MAPK8 (0.56) | MEN1KMT2AMAPK8EPHX2TP53 | |
| SCHEMBL14413553 | 0.82 | EPHX2 (0.58) | NPC1RAB9AEPHX2ALDH1A1PKM | |
| SCHEMBL5471711 | 0.81 | PKM (0.69) | MEN1KMT2ANPC1RAB9AGAA | |
| SCHEMBL5466684 | 0.80 | EPHX2 (0.53) | MEN1KMT2AP2RX7EPHX2ALDH1A1 | |
| SCHEMBL5471150 | 0.79 | MEN1 (0.75) | MEN1KMT2AHTTALDH1A1TP53 | |
| SCHEMBL13746191 | 0.79 | TP53 (0.68) | MEN1KMT2AGAAP2RX7EPHX2 | |
| SCHEMBL5476543 | 0.79 | MEN1 (0.56) | MEN1KMT2AGAAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030096019-A1 | Methods of using norfluoxetine | SEPRACOR INC. | 2003-05-22 | — | — | US | claimed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070078188-A1 | Compositions comprising and methods of using norfluoxetine | CURRIE MARK G | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096019-A1 | Methods of using norfluoxetine | NGF, TPH2, ALOX5 | MEN1 3784/4885KMT2A 2911/4885NPC1 2133/4885 |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | MEN1 3623/4885KMT2A 323/4885NPC1 3750/4885 |
| US-20070078188-A1 | Compositions comprising and methods of using norfluoxetine | ALOX5, NGF, PTGER4 | MEN1 3553/4885KMT2A 3402/4885NPC1 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.